Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases
Donato Cosco,1 Flavio Rocco,2 Maurizio Ceruti,2 Margherita Vono,1 Massimo Fresta,1,3 Donatella Paolino1,3
1Department of Health Sciences, University "Magna Græcia", Catanzaro; 2Dipartimento di Scienza e Tecnologia del Farmaco, Torino; 3UOC Farmacia Ospedaliera Fondazione per la Ricerca e la Cura dei Tumori "Tommaso Campanella", Campus Universitario "S Venuta", Catanzaro, Italy
Background: In this investigation, the antileukemic activity of a new nanomedicine based on the conjugation of 1,1',2-tris-nor-squalenic acid with cytarabine (Ara-C) was evaluated.
Methods: Squalenoyl-Ara-C conjugate (Sq-Ara-C) self-assembled nanosystems were obtained by the nanoprecipitation method and characterized in vitro and in vivo.
Results: This new nanomedicine, which had a mean diameter of approximately 150 nm, improved the in vitro antitumoral activity of Ara-C in different cancer cell lines (L1210, K562, and MCF-7). Sq-Ara-C nanomedicine allowed reduction of the IC50 value with respect to the free drug and was also active against drug-resistant leukemic cells (L1210R). A noticeable increase in the survival rate of mice with aggressive metastatic L1210R leukemia was observed after treatment with Sq-Ara-C (50 mg/kg) as compared with the free active compound (100 mg/kg). Finally, evaluation of the biodistribution and pharmacokinetic profiles of the drug demonstrated that these nanoaggregates preferentially localized to the liver and spleen, and protected the drug from physiological metabolism.
Conclusion: Squalenoylation of cytarabine offers several pharmacological benefits both in vitro and in vivo.
Keywords: squalenoyl-cytarabine, self-assembly, antitumoral nanomedicine, leukemia, nanoaggregate, biodistribution
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Roy K, Kanwar RK, Kanwar JR
Published Date: 26 August 2015
Comparative efficacy and safety of local and systemic methotrexate injection in cesarean scar pregnancy
Peng P, Gui T, Liu X, Chen W, Liu Z
Published Date: 27 January 2015
Wu P, Li S, Zhang H
Published Date: 5 December 2014
Erturk A, Adnan Akdogan R, Parlak E, Cure E, Cumhur Cure M, Ozturk C
Published Date: 29 May 2014
Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant
Guilcher GM, Stewart DA
Published Date: 8 May 2014
Chen J, Shao R, Zhang XD, Chen C
Published Date: 24 July 2013
Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer
Shi J, Wang Z, Wang L, Wang H, Li L, Yu X, Zhang J, Ma R, Zhang Z
Published Date: 19 April 2013
Saifullah B, Hussein MZ, Hussein Al Ali SH
Published Date: 12 October 2012
Published Date: 8 December 2011
Published Date: 17 September 2010